Purchase this article with an account.
Hemalatha Kolli, Monali Chakrabarti, Dipali Aralikatti, Mostafa El Gammal, Randhir Chavan, Samer Elsherbiny, Arijit Mitra, Peck-Lin Lip, Bushra Mushatq; Management of Diabetic macular oedema with Intravitreal Ranibizumab -Outcome after three years. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4823. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report 3 year outcome data following management of Diabetic Macular Oedema with Ranibizumab
Inclusion criteriaAll patients with DMO who have completed 36 months follow up after commencing loading dose of RanibizumabData CollectionRetrospective notes review of Medisoft entries and CDAPatient demographics, visual acuity(VA),and Central retinal thickness (CRT) at baseline, after loading dose,12, 24 and 36 monthsTreatment for DMO prior to RanibizumabBevazuzimab 30Macular laser 64IVTA 17Other interventional treatments for DMOTriamcinolone 5Ozurdex 4Bevazuzimab 13Iluvien 15Macular laser 30
The study included116 Patient,148 eyes.There were 51 males and 65 femalesThe mean age was 66 years, range 29-88 years.Bilateral 32 eyesRight : Left,76 : 7212 patients had Type 1 DM while 104 had Type 2 DM.The mean duration of diabetes was16 years, range 1-30years.Total number of injectionsYear 1 –mean 5 (3-12)Year 2 –mean 1.8 (0-6)Year 3 – mean 1.5 (0-7)Surgical interventionCataract surgery with IOL -30PPV -1PPV+Phaco+IOL+Peel+Endolaser -1PPV+ERM peel+IVTA -1The visual acuity evaluation at 3 year review 64 eyes (43%) showed improvement,24 eyes (16.2% gaining more than15L)84 eyes (57%) had some progression15 eyes (10% had>15L deterioration
Ranibizumab has shown to improve VA in 43% of patients treated for DMO over 3 years10% of patients had deterioration of VA over a three year periodThere was progressive decrease in CRT over a three year periodRanibizumab is well tolerated with low risk of complications (<1%)
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only